{"id":36159,"date":"2025-10-29T14:07:19","date_gmt":"2025-10-29T13:07:19","guid":{"rendered":"https:\/\/ggba.swiss\/?p=36159"},"modified":"2025-10-29T14:07:20","modified_gmt":"2025-10-29T13:07:20","slug":"tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/","title":{"rendered":"Tubulis raises EUR 308 million to advance ADC therapies and expand its clinical pipeline"},"content":{"rendered":"\n<p>Tubulis, a biopharmaceutical company specializing in antibody-drug conjugates (ADCs), has raised EUR 308 million in a Series C financing round, Europe\u2019s largest to date for a private biotech and the largest worldwide for an ADC-focused company. The round was led by <a href=\"https:\/\/www.venrock.com\/\">Venrock Healthcare Capital Partners<\/a>, with participation from <a href=\"https:\/\/www.wellington.com\/en-ch\/\">Wellington Management<\/a>, <a href=\"https:\/\/www.ascentacap.com\/\">Ascenta Capital<\/a>, and existing investors including <a href=\"https:\/\/www.nextechinvest.com\/\">Nextech Invest<\/a>, <a href=\"https:\/\/eqtgroup.com\/private-capital\/eqt-life-sciences\">EQT Life Sciences<\/a>, <a href=\"https:\/\/frazierls.com\/\">Frazier Life Sciences<\/a>, and <a href=\"https:\/\/www.anderapartners.com\/en\/\">Andera Partners<\/a>.<\/p>\n\n\n\n<p>Headquartered in Munich with a new research presence at Lausanne\u2019s <a href=\"https:\/\/www.biopole.ch\/\">Biop\u00f4le<\/a> life sciences campus, Tubulis develops next-generation ADCs that combine targeted drug delivery with superior stability and therapeutic activity. The company\u2019s lead candidate, TUB-040, targets the NaPi2b antigen, which is overexpressed in ovarian cancer and lung adenocarcinoma. It is currently being evaluated in a Phase I\/IIa clinical trial (NAPISTAR1-01) and was granted Fast Track designation by the U.S. FDA in 2024.<\/p>\n\n\n\n<p>The new funding will support the expansion of TUB-040 into additional tumor indications and earlier lines of therapy, as well as the clinical advancement of TUB-030, which targets the 5T4 antigen, and several preclinical programs. Tubulis will also continue developing its proprietary ADC platform technologies to unlock new therapeutic applications for cancer treatment.<\/p>\n\n\n\n<p>\u201cThis landmark financing reflects strong conviction in Tubulis and the disruptive potential of our ADC platforms,\u201d said Dr. Dominik Schumacher, CEO and Co-founder. \u201cWith TUB-040 progressing in the clinic and data forthcoming, we are ready to expand our development programs and bring truly differentiated ADCs to patients.\u201d<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">A European leader in precision oncology<\/h4>\n\n\n\n<p>Founded in 2019, Tubulis is redefining targeted cancer therapy through uniquely matched ADCs that demonstrate durable on-tumor delivery and long-lasting anti-tumor activity. By combining German scientific excellence with Western Switzerland\u2019s collaborative research environment, the company is strengthening Europe\u2019s position in precision oncology.<\/p>\n\n\n\n<p>With this record-breaking financing and a growing footprint at Biop\u00f4le, Tubulis joins the ranks of global leaders advancing the next generation of antibody-drug conjugates to improve outcomes for patients with solid tumors.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Munich- and Lausanne-based biotech secures Europe\u2019s largest-ever Series C financing to accelerate development of next-generation antibody-drug conjugates.<\/p>\n","protected":false},"author":6,"featured_media":36160,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,883,901],"class_list":["post-36159","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-oncology","tag-technology-park"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tubulis raises EUR 308 million | GGBa<\/title>\n<meta name=\"description\" content=\"Tubulis secures Europe\u2019s largest-ever Series C financing to accelerate development of next-generation antibody-drug conjugates.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tubulis raises EUR 308 million | GGBa\" \/>\n<meta property=\"og:description\" content=\"Tubulis secures Europe\u2019s largest-ever Series C financing to accelerate development of next-generation antibody-drug conjugates.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T13:07:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T13:07:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Tubulis raises EUR 308 million to advance ADC therapies and expand its clinical pipeline\",\"datePublished\":\"2025-10-29T13:07:19+00:00\",\"dateModified\":\"2025-10-29T13:07:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/\"},\"wordCount\":339,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Financing\",\"Oncology\",\"Technology Park\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/\",\"url\":\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/\",\"name\":\"Tubulis raises EUR 308 million | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg\",\"datePublished\":\"2025-10-29T13:07:19+00:00\",\"dateModified\":\"2025-10-29T13:07:20+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Tubulis secures Europe\u2019s largest-ever Series C financing to accelerate development of next-generation antibody-drug conjugates.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"The Tubulis team at the Biop\u00f4le life sciences campus in Lausanne, marking the opening of their Swiss office in 2025 to advance next-generation antibody-drug conjugate research. | \u00a9 Biop\u00f4le\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tubulis raises EUR 308 million to advance ADC therapies and expand its clinical pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tubulis raises EUR 308 million | GGBa","description":"Tubulis secures Europe\u2019s largest-ever Series C financing to accelerate development of next-generation antibody-drug conjugates.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Tubulis raises EUR 308 million | GGBa","og_description":"Tubulis secures Europe\u2019s largest-ever Series C financing to accelerate development of next-generation antibody-drug conjugates.","og_url":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-10-29T13:07:19+00:00","article_modified_time":"2025-10-29T13:07:20+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Tubulis raises EUR 308 million to advance ADC therapies and expand its clinical pipeline","datePublished":"2025-10-29T13:07:19+00:00","dateModified":"2025-10-29T13:07:20+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/"},"wordCount":339,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg","keywords":["Biotech","Financing","Oncology","Technology Park"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/","url":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/","name":"Tubulis raises EUR 308 million | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg","datePublished":"2025-10-29T13:07:19+00:00","dateModified":"2025-10-29T13:07:20+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Tubulis secures Europe\u2019s largest-ever Series C financing to accelerate development of next-generation antibody-drug conjugates.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg","width":1180,"height":811,"caption":"The Tubulis team at the Biop\u00f4le life sciences campus in Lausanne, marking the opening of their Swiss office in 2025 to advance next-generation antibody-drug conjugate research. | \u00a9 Biop\u00f4le"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Tubulis raises EUR 308 million to advance ADC therapies and expand its clinical pipeline"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/36159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=36159"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/36159\/revisions"}],"predecessor-version":[{"id":36163,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/36159\/revisions\/36163"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/36160"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=36159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=36159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=36159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}